SCHEMBL353937

SCHEMBL353937

C[C@H](N)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355242 1.00
SCHEMBL271371 1.00
Fluoride SCHEMBL31281119 0.95
Water SCHEMBL31281739 0.95
Hydrochloric Acid SCHEMBL1978156 0.95
Hydrochloric Acid SCHEMBL25273278 0.95
Hydrochloric Acid SCHEMBL5206284 0.95
SCHEMBL7671989 0.76 ALDH1A1 (0.31)
SCHEMBL21100089 0.76
SCHEMBL239610 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387385-A1 TREATMENT FOR GLOMERULAR DISEASES ZYDUS LIFESCIENCES LIMITED (IN) 2025-12-25 US claimed
EP-4565233-A1 TREATMENT FOR APLASTIC ANEMIA (AA) Zydus Lifesciences Limited (IN) 2025-06-11 EP claimed
EP-4539934-A1 TREATMENT FOR GLOMERULAR DISEASES Zydus Lifesciences Limited (IN) 2025-04-23 EP claimed
CN-119816306-A Treatment of Aplastic Anemia (AA) 载度思生命科学有限公司 2025-04-11 CN claimed
CN-119486735-A For the treatment of glomerular diseases 载度思生命科学有限公司 2025-02-18 CN claimed
CN-115960325-B Ultrathin chiral fluorescent covalent organic framework nano-sheet and preparation method and application thereof 中国科学院福建物质结构研究所 2024-11-12 CN claimed
US-12104106-B2 Compositions of chiral molecules and perovskite nanocrystals and methods of making the same ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) 2024-10-01 US claimed
US-20240173314-A1 TREATMENT OF SICKLE CELL ANAEMIA ZYDUS LIFESCIENCES LTD. (IN) 2024-05-30 US claimed
WO-2024028744-A1 TREATMENT FOR APLASTIC ANEMIA (AA) ZYDUS LIFESCIENCES LIMITED (IN) 2024-02-08 WO claimed
EP-4308120-A1 TREATMENT FOR SICKLE CELL ANAEMIA Zydus Lifesciences Limited (IN) 2024-01-24 EP claimed
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-12 US claimed
WO-2008151170-A2 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-12-11 WO claimed
US-7166628-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-01-23 US claimed
EP-1567507-B1 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMA (US) 2006-06-14 EP claimed
EP-0857790-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS KANEKA CORP (JP) 2005-08-17 EP claimed
US-20040102492-A1 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-05-27 US claimed
US-20010031487-A1 Process for producing optically active amino compounds KANEKA CORPORATION 2001-10-18 US claimed
US-6221638-B1 BY STEREOSELECTIVELY CARRYING OUT AMINO GROUP TRANSFER BY ACTION OF AN (R)-FORM-SPECIFIC TRANSAMINASE IN THE CO-PRESENCE OF A KETONE (AMINO ACCEPTOR) AND AMINO COMPOUND (AMINO DONOR); YIELDS AMINO COMPOUNDS HAIVNG ARYL GROUP AT THE 1-POSITION KANEKA CORPORATION (JP) 2001-04-24 US claimed
EP-0987332-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS Kaneka Corporation (JP) 2000-03-22 EP claimed
EP-0857790-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS KANEKA CORPORATION (JP) 1998-08-12 EP claimed